Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase PKCi]
Substrate: VASP

Description: Vasodilator-stimulated phosphoprotein (VASP).

Ensembl ID: ENSG00000125753

UniprotKB/SwissProt: VASP_HUMAN (P50552)

Function: Ena/VASP proteins are actin-associated proteins involved in a range of processes dependent on cytoskeleton remodeling and cell polarity such as axon guidance and lamellipodial and filopodial dynamics in migrating cells. VASP promotes actin nucleation and increases the rate of actin polymerization in the presence of capping protein. Plays a role in actin-based activity of Listeria monocytogenes in platelets (By similarity).

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm. Cytoplasm, cytoskeleton. Cell junction, focal adhesion. Cell projection, lamellipodium membrane. Cell projection, filopodium membrane. Note=Targeted to stress fibers and focal adhesions through interaction with a number of proteins including M
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of VASP

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1VASPVASP_HUMANY39SRVQI Y HNPTA 4.39% Phospho.ELM 7.0View   
2VASPVASP_HUMANY39SRVQI Y HNPTA 4.39% Swiss-Prot 55.0 View   
3VASPVASP_HUMANS157IERRV S NAGGP 21.10% HPRD:03415(in vivo)View   
4VASPVASP_HUMANS157IERRV S NAGGP 21.10%PKG_group Phospho.ELM 7.0 ViewAnalyzing
5VASPVASP_HUMANS157IERRV S NAGGP 21.10%PKA_group Phospho.ELM 7.0 ViewAnalyzing
6VASPVASP_HUMANS157IERRV S NAGGP 21.10%PKACa HPRD:03415(in vitro)  ViewAnalyzing
7VASPVASP_HUMANS157IERRV S NAGGP 21.10%PKG1 HPRD:03415(in vitro;in vivo)  ViewAnalyzing
8VASPVASP_HUMANS157IERRV S NAGGP 21.10%PKG1 Phospho.ELM 7.0  ViewAnalyzing
9VASPVASP_HUMANS157IERRV S NAGGP 21.10%PKC_group Swiss-Prot 55.0  ViewAnalyzing
10VASPVASP_HUMANS157IERRV S NAGGP 21.10%PKG_group Swiss-Prot 55.0  ViewAnalyzing
11VASPVASP_HUMANS157IERRV S NAGGP 21.10%ROCK1 Swiss-Prot 55.0   ViewAnalyzing
12VASPVASP_HUMANS157IERRV S NAGGP 21.10%PKA_group Swiss-Prot 55.0  ViewAnalyzing
13VASPVASP_HUMANS239KLRKV S KQEEA 31.49%PKG_group Phospho.ELM 7.0 ViewAnalyzing
14VASPVASP_HUMANS239KLRKV S KQEEA 31.49%PKA_group Phospho.ELM 7.0 ViewAnalyzing
15VASPVASP_HUMANS239KLRKV S KQEEA 31.49%PKACa HPRD:03415(in vitro)  ViewAnalyzing
16VASPVASP_HUMANS239KLRKV S KQEEA 31.49%PKA_group Swiss-Prot 55.0  ViewAnalyzing
17VASPVASP_HUMANS239KLRKV S KQEEA 31.49%PKG1 Phospho.ELM 7.0  ViewAnalyzing
18VASPVASP_HUMANS239KLRKV S KQEEA 31.49%PKG1 HPRD:03415(in vitro;in vivo)  ViewAnalyzing
19VASPVASP_HUMANS239KLRKV S KQEEA 31.49%PKG_group Swiss-Prot 55.0  ViewAnalyzing
20VASPVASP_HUMANS239KLRKV S KQEEA 31.49% HPRD:03415(in vivo)View   
21VASPVASP_HUMANT278RRRKA T QVGEK 27.16%PKA_group Phospho.ELM 7.0 ViewAnalyzing
22VASPVASP_HUMANT278RRRKA T QVGEK 27.16%PKG_group Phospho.ELM 7.0 ViewAnalyzing
23VASPVASP_HUMANT278RRRKA T QVGEK 27.16%PKACa HPRD:03415(in vitro)  ViewAnalyzing
24VASPVASP_HUMANT278RRRKA T QVGEK 27.16%PKG1 HPRD:03415(in vitro)  ViewAnalyzing
25VASPVASP_HUMANT278RRRKA T QVGEK 27.16%PKA_group Swiss-Prot 55.0  ViewAnalyzing
26VASPVASP_HUMANT278RRRKA T QVGEK 27.16%PKG_group Swiss-Prot 55.0  ViewAnalyzing
27VASPVASP_HUMANS322LPRMK S SSSVT 26.55% Swiss-Prot 55.0 (Similarity)View   
28VASPVASP_HUMANS323PRMKS S SSVTT 22.55% Swiss-Prot 55.0 (Similarity)View